NeuBase Therapeutics Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Todd Branning
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 2.3yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | Nessun dato |
| Durata media del Consiglio di amministrazione | 3.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?
Aug 26
NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04
Aug 11NeuBase Therapeutics promotes Dr. William Mann to President and COO
Jun 29We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully
May 12Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?
Jan 24Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Oct 02Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Jun 02Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?
Feb 23We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth
Jan 19NeuBase Therapeutics EPS in-line
Dec 23NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy
Dec 16Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?
Dec 15Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | n/a | n/a | -US$30m |
| Sep 30 2022 | US$922k | US$311k | -US$34m |
Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Todd sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Todd con le performance aziendali.
AMMINISTRATORE DELEGATO
Todd Branning (53 yo)
2.3yrs
Mandato
US$922,445
Compensazione
Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 4.8yrs | US$1.15m | 6.14% $ 87.1k | |
| Independent Chairperson | 4.8yrs | US$74.42k | 0.040% $ 567.0 | |
| Independent Director | 4.8yrs | US$68.38k | 0.060% $ 849.3 | |
| Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Member of Gene Editing & Scientific Advisory Board | 4.6yrs | Nessun dato | Nessun dato | |
| Member of Gene Editing Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 3.5yrs | Nessun dato | Nessun dato | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Chair of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Gene Editing & Scientific Advisory Board | 3.6yrs | Nessun dato | Nessun dato | |
| Member of Gene Editing & Scientific Advisory Board | 3.5yrs | Nessun dato | Nessun dato | |
| Independent Director | 3yrs | US$59.79k | 0% $ 0 |
3.5yrs
Durata media
56yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NBSE sono considerati esperti (durata media dell'incarico 3.5 anni).